keyword
MENU ▼
Read by QxMD icon Read
search

viral hepatitis prevention, treatment

keyword
https://www.readbyqxmd.com/read/28087399/advances-with-using-crispr-cas-mediated-gene-editing-to-treat-infections-with-hepatitis-b-virus-and-hepatitis-c-virus
#1
REVIEW
Buhle Moyo, Kristie Bloom, Tristan Scott, Abdullah Ely, Patrick Arbuthnot
Chronic infections with hepatitis B and hepatitis C viruses (HBV and HCV) account for the majority of cases of cirrhosis and hepatocellular carcinoma. Current therapies for the infections have limitations and improved efficacy is necessary to prevent complications in carriers of the viruses. In the case of HBV persistence, the replication intermediate comprising covalently closed circular DNA (cccDNA) is particularly problematic. Licensed therapies have little effect on cccDNA and HBV replication relapses following treatment withdrawal...
January 10, 2017: Virus Research
https://www.readbyqxmd.com/read/28081594/management-of-direct-antiviral-agent-failures
#2
REVIEW
María Buti, Rafael Esteban
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective. Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied...
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28073406/-prevention-of-mother-to-child-transmission-of-hepatitis-b-virus
#3
H Zhuang
Mother-to-child transmission (MTCT) is a major mode of hepatitis B virus (HBV) transmission, especially in high endemic areas. Administration of hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine to infants at birth, followed by completion of the vaccine series, prevented approximately 95% of HBV transmission from HBsAg-positive mothers to their infants. However, immunoprophylaxis failure was still observed in 5~10% infants born to mothers with high levels of viremia. It was demonstrated that antiviral nucleot(s)ide analogues (NUCs) provided to pregnant women with high viral loads in late pregnancy further reduced MTCT...
December 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28060213/ursodeoxycholyl-lysophosphatidylethanolamide-protects-against-cd95-fas-induced-fulminant-hepatitis
#4
Tanyarath Utaipan, Ann-Christin Otto, Hongying Gan-Schreier, Warangkana Chunglok, Anita Pathil, Wolfgang Stremmel, Walee Chamulitrat
Increased activation of CD95/Fas by Fas ligand in viral hepatitis and autoimmunity is involved in pathogenesis of fulminant hepatitis and liver failure. We designed a bile-acid phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE with LPE containing oleate at the sn-1) as a hepatoprotectant that was shown to protect against fulminant hepatitis induced by endotoxin. We herein further assessed the ability of UDCA-LPE to prevent death receptor CD95/Fas-induced fulminant hepatitis. C57BL/6 mice were intravenously administered with CD95/Fas agonistic monoclonal antibody (Jo-2) with or without 1 h pretreatment with 50 mg/kg UDCA-LPE...
January 4, 2017: Shock
https://www.readbyqxmd.com/read/28052634/treatment-of-chronic-hepatitis-b-infection-2017
#5
REVIEW
Guo-Feng Chen, Cheng Wang, George Lau
Since the registration of the first effective nucleoside analogue against the hepatitis B virus almost two decades ago, major progress has been made in the management of chronic hepatitis B infection. However, hepatitis B-related morbidity and mortality remain a major global health threat. This is partly due to the escalating costs and the decrease in compliance related to the need for prolonged therapy for most patients who cannot be "cured". New biomarkers such as quantitative hepatitis B surface antigen might help to determine if hepatitis B e antigen negative patients can be taken off nucleos(t)ide analogues...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28051792/-u-u-%C3%A2-management-strategies-for-liver-fibrosis
#6
Alejandra Altamirano-Barrera, Beatriz Barranco-Fragoso, Nahum Méndez-Sánchez
 Liver fibrosis resulting from chronic liver injury are major causes of morbidity and mortality worldwide. Among causes of hepatic fibrosis, viral infection is most common (hepatitis B and C). In addition, obesity rates worldwide have accelerated the risk of liver injury due to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Also liver fibrosis is associated with the consumption of alcohol, or autoimmune hepatitis and chronic cholangiophaties. The response of hepatocytes to inflammation plays a decisive role in the physiopathology of hepatic fibrosis, which involves the recruitment of both pro- and anti-inflammatory cells such as monocytes and macrophages...
January 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28029529/ledipasvir-plus-sofosbuvir-fixed-dose-combination-for-6-weeks-in-patients-with-acute-hepatitis-c-virus-genotype-1-monoinfection-hepnet-acute-hcv-iv-an-open-label-single-arm-phase-2-study
#7
Katja Deterding, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze Zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch, Dorothee von Witzendorff, Michael P Manns, Heiner Wedemeyer
BACKGROUND: Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa is highly effective, but can be associated with frequent side-effects. We investigated the safety and efficacy of an interferon-free regimen for treatment of acute HCV infection. METHODS: In this prospective, open-label, multicentre, single-arm pilot study, we enrolled adults (≥18 years) with acute HCV genotype 1 monoinfection from ten centres in Germany. Patients were given ledipasvir (90 mg) plus sofosbuvir (400 mg) as a fixed-dose combination tablet once daily for 6 weeks...
October 28, 2016: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28027590/hepatitis-b-reactivation-in-occult-viral-carriers-undergoing-hematopoietic-stem-cell-transplantation-a-prospective-study
#8
Wai-Kay Seto, Thomas Sau-Yan Chan, Yu-Yan Hwang, Danny Ka-Ho Wong, James Fung, Kevin Sze-Hang Liu, Harinder Gill, Yuk-Fai Lam, Eric H Y Lau, Ka-Shing Cheung, Albert K W Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen
Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc) positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) have not been prospectively studied. HBsAg-negative, anti-HBc positive patients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 weeks. The primary endpoint was HBV reactivation, defined as detectable HBV DNA (≥10 IU/mL). Secondary endpoints included overall survival, HBsAg-positivity, and changes in liver biochemistry and antibody to HBsAg levels...
December 27, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28005030/-assessment-of-awareness-about-the-epidemiology-outcomes-and-therapy-of-chronic-hepatitis-b-and-c-in-adolescents-and-adults
#9
S V Baramzina
AIM: To estimate the level of knowledge in adults and adolescents about the issues related to viral hepatitis B and C: the transmission modes, course, and outcomes of acute and chronic hepatitis B (CHB) and C (CHC), as well as about current measures for their prevention and treatment. SUBJECTS AND METHODS: A total of 850 dwellers of Kirov and the Kirov Region were anomalously surveyed using an original questionnaire in 2013- 2015. The questionnaire included 24 questions on the etiology, epidemiology, outcomes, prevention, and treatment of CHB and CHC and on the sources of information...
2016: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/27993129/hepatitis-viruses-in-ethiopia-a-systematic-review-and-meta-analysis
#10
Yeshambel Belyhun, Melanie Maier, Andargachew Mulu, Ermias Diro, Uwe Gerd Liebert
BACKGROUND: The existing seroepidemiological data on viral hepatitis in Ethiopia showed a wide variation in prevalence pattern and the clinical and public health burden have been underestimated. The aim of this systematic review and meta-analysis was to provide a clear and comprehensive estimation of viral hepatitis epidemiology and the potential clinical burdens in Ethiopia. METHODS: A comprehensive literature search was carried out from five decades (1968-2015) published studies from biomedical databases; PubMed, Google scholar, Medline and Web of Science...
December 19, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27992983/risk-factors-for-hepatitis-c-virus-infection-in-the-colombian-caribbean-coast-a-case-control-study
#11
Ismael de Jesús Yepes, Beatriz Lince, Clara Caez, Giovanni De Vuono
INTRODUCTION: An estimated 6.8-8.9 million people are infected with hepatitis C virus in Latin America, of which less than 1% receives antiviral treatment. Studies so far in Colombia have attempted to determine the prevalence of the disease in some risk groups, thus preventing the identification of other factors potentially involved in the spread of the infection. OBJECTIVES: To identify traditional and non-traditional risk factors for chronic hepatitis C in the Colombian Caribbean coast...
December 1, 2016: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/27988410/sofosbuvir-an-antiviral-drug-with-potential-efficacy-against-zika-infection
#12
Sandra E Reznik, Charles R Ashby
No abstract text is available yet for this article.
December 14, 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/27975110/viral-hepatitis-in-children-a-through-e
#13
Ankur Chugh, Maryann Maximos, Meryl Perlman, Regino P Gonzalez-Peralta
Hepatitis is defined as inflammation of the liver. This inflammation can be acute and self-limited, chronic (leading to cirrhosis and an increased risk for hepatocellular carcinoma), or fulminant (requiring lifesaving liver transplantation). Although there are many causes of hepatitis, this article focuses on the main childhood viral hepatidities: types A, B, C, D, and E. This review discusses the main characteristics of each virus, including salient epidemiology, clinical characteristics, diagnosis, treatment, and prevention strategies...
December 1, 2016: Pediatric Annals
https://www.readbyqxmd.com/read/27936480/treatment-of-fulminant-acute-hepatitis-b-with-nucles-t-id-analogues-is-safe-and-does-not-lead-to-secondary-chronification-of-hepatitis-b
#14
C Jochum, F Maischack, O E Anastasiou, J Verheyen, J Timm, L Bechmann, G Gerken, A Canbay
Background: Acute hepatitis B virus (HBV) infection is still a major cause of acute liver failure (ALF), necessitating a high rate of emergency liver transplantation (LTx). Acute infection is followed by high viral replication rates leading to hepatocyte death and, ultimately, ALF. The objective of treating HBV-induced ALF thus is to eliminate, or significantly suppress, HBV replication and therefore reduce cell death and support regeneration. Objective: In this retrospective study, we want to evaluate the timing, the safety, and the long-term virological outcome of this approach...
December 2016: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27932311/daclatasvir-prevents-hepatitis-c-virus-by-blocking-transfer-of-viral-genome-to-assembly-sites
#15
Bertrand Boson, Solène Denolly, Fanny Turlure, Christophe Chamot, Marlène Dreux, François-Loïc Cosset
BACKGROUND & AIMS: Daclatasvir is a direct-acting antiviral agent and potent inhibitor of NS5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranous web shaping, and assembly of new virions, likely via transfer of the HCV RNA genome to viral particle assembly sites. Daclatasvir inhibits the formation of new membranous web structures and, ultimately, of replication complex vesicles, but also inhibits an early assembly step. We investigated the relationship between daclatasvir-induced clustering of HCV proteins, intracellular localization of viral RNAs and inhibition of viral particle assembly...
December 5, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27929247/initial-management-of-patients-with-hiv-infection
#16
Ronald H Goldschmidt, Carolyn Chu, Betty J Dong
Human immunodeficiency virus (HIV) infection has become a treatable chronic disease with near-normal life expectancy when patients receive antiretroviral therapy (ART). Family physicians and other primary care clinicians commonly provide long-term comprehensive care for persons with HIV infection. This article describes the scope of initial care, including obtaining a thorough history; physical examination for HIV-associated manifestations; attention to HIV-specific immunization schedules; routine and HIV-specific laboratory evaluation; and ensuring standard health care maintenance to prevent HIV- and non-HIV-related morbidity and mortality...
November 1, 2016: American Family Physician
https://www.readbyqxmd.com/read/27928007/mice-expressing-minimally-humanized-cd81-and-occludin-genes-support-hepatitis-c-virus-uptake-in-vivo
#17
Qiang Ding, Markus von Schaewen, Gabriela Hrebikova, Brigitte Heller, Lisa Sandmann, Mario Plaas, Alexander Ploss
Hepatitis C virus (HCV) causes chronic infections in at least 150 million individuals world-wide. HCV has a narrow host range and robustly infects only humans and chimpanzees. The underlying mechanisms for this narrow host range are incompletely understood. At the level of entry differences in the amino acid sequences between the human and mouse orthologues of two essential host factors, the tetraspannin CD81 and the tight junction protein occludin (OCLN) explain at least in part HCV's limited ability to enter mouse hepatocytes...
December 7, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27917563/outcome-of-hepatitis-b-and-c-virus-associated-hepatocellular-carcinoma-occurring-after-renal-transplantation
#18
N Kanaan, C Raggi, E Goffin, M De Meyer, M Mourad, M Jadoul, C Beguin, B Kabamba, I Borbath, Y Pirson, Z Hassoun
Kidney transplant recipients (KTR) are subjected to immunosuppressive therapy that can enhance hepatitis B and C virus replication, leading to cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to assess the prevalence and outcome of HCC in KTR. Case-control study. Patients with chronic HBV and/or HCV infection who underwent kidney transplantation between 1976 and 2011 and subsequently developed HCC were compared to a control group of patients with chronic HBV and/or HCV infection, matched for gender and age at HCC diagnosis, who did not receive kidney transplantation...
December 5, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27911488/hepatocellular-carcinoma-as-an-emerging-morbidity-in-the-thalassemia-syndromes-a-comprehensive-review
#19
REVIEW
Hassan M Moukhadder, Racha Halawi, Maria Domenica Cappellini, Ali T Taher
The incidence of hepatocellular carcinoma (HCC) in patients with thalassemia is on the rise. The 2 well recognized HCC risk factors in thalassemia are iron overload and chronic viral infection with hepatitis C. The carcinogenicity of iron is related to its induction of oxidative damage, which results in genotoxicity, and to immunologic dysregulation, which attenuates cancer immune surveillance. Chronic hepatitis B and C infections lead to necroinflammation, which can prompt progression to HCC, but an independent role of hepatitis B virus in hepatic carcinogenesis among patients with thalassemia has not been demonstrated...
December 1, 2016: Cancer
https://www.readbyqxmd.com/read/27910749/role-of-toll-like-receptors-in-hepatitis-c-virus-pathogenesis-and-treatment
#20
Usman Ali Ashfaq, Muhammad Sarfaraz Iqbal, Saba Khaliq
Viral infections are rising every day, and viruses appear to be the most dangerous pathogens in the world. Hepatitis C virus (HCV) is accepted as one of the major destructive factors of promoting severe hepatic disorders by infecting more than 180 million individuals throughout the world. Chronic infection caused by HCV poses a serious global health emergency and appears to be a powerful threat to humanity. Almost 20 years have passed since the disclosure of HCV, but even now, treatment preferences remain limited...
2016: Critical Reviews in Eukaryotic Gene Expression
keyword
keyword
81791
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"